0.81USD
2.39 BUSD
30.31 BUSD
1.51 B
About Takeda Pharmaceutical Co., Ltd.
Sector
CEO
Christophe Weber
Headquarters
Osaka
Website
Employees (FY)
49.1 K
Founded
1781
ISIN
JP3463000004
FIGI
BBG000C1FLX4
Takeda Pharmaceutical Co., Ltd. engages in the research and development, manufacture, import and export sale, and marketing of pharmaceutical drugs. It operates through the following segments: Prescription Drug, Consumer Healthcare, and Other. The Prescription Drugs segment includes the manufacture and sale of pharmaceutical products. The Consumer Healthcare segment includes the manufacture and sale of OTC drugs and quasi-drugs. The Other segment includes manufacture and sale of reagents, clinical diagnostics, and chemical products. The company was founded by Takeda Chobei on June 12, 1781 and is headquartered in Osaka, Japan.
TAK Currently At Short EntryTAK showing large wick rejection on weekly. Reward/risk here is 3.0 with trade as pictured and entries scattered across the red zone.
TAK : SQUARE ROOT / POSITION TRADEThe Square Root set-up appears in large cap stocks that underwent capitulation. Because large caps are heavily traded, the high liquidity reduces sharp movements. This set-up is best for position trading and usually is a sweet spot for establishing a core position on a stock that potentially has lo
Big Bull Run, 30+ short term, 50+ long term
30 within month
50+ within year
Takeda has made significant moves in the development of it's global pipeline. From the MASSIVE moves with various COVID vaccine manufacturers, to acquiring smaller Immunology biotech startups, and increase in Boston research sphere. I am the most bullish on Takeda
4502 (TSE) - Be CarefullGreetings
Humbled, we would like to thanks for your support who has already liked, commented and followed us. Your support, strengthens us, to help in analyzing the market. If you have any questions, do not be hesitant to send us message (inbox). Our Service : Signal recomendation, Trading Course, P
consolidation faze before the breakout ? yeshas potential if 21 can break, can possibly enter here but at the risk of waiting a few months to a year for this trend channel to break to the upside, i prefer waiting for confirmation first! but we all have our own style. goodluck :)
TAK: ReversalIdea,
Inverse cup and handle.
Inverse head and shoulders
RSI divergence double bottom upward trend
top 18...
can it break ATH?
TAK - Takeda Pharma - TO THE MOON? - Major Covid 19 Discovery Researchers tout 'major scientifc discovery' in $14M study for COVID-19 treatment
www.cbc.ca
Close to 4,500 people participated in the study, lead researcher calls findings 'substantial' and 'robust'
CBC News · Posted: Jan 23, 2021 4:07 PM ET | Last Updated: January 23
The $14-million study was fu
TAK LongPossible inverse head and shoulders formation. ARK invest has been loading up shares. looking into June contracts or leaps.
See all ideas
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of TKPHF is 26.52 USD — it has decreased by 1.96% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on OTC exchange Takeda Pharmaceutical Co., Ltd. stocks are traded under the ticker TKPHF.
Takeda Pharmaceutical Co., Ltd. is going to release the next earnings report on May 9, 2024. Keep track of upcoming events with our Earnings Calendar.
TKPHF stock is 2.00% volatile and has beta coefficient of 0.77. Check out the list of the most volatile stocks — is Takeda Pharmaceutical Co., Ltd. there?
One year price forecast for Takeda Pharmaceutical Co., Ltd. has a max estimate of 39.22 USD and a min estimate of 27.21 USD.
TKPHF earnings for the last quarter are −0.21 USD whereas the estimation was 0.19 USD which accounts for −211.01% surprise. Estimated earnings for the next quarter are 0.20 USD. See more details about Takeda Pharmaceutical Co., Ltd. earnings.
Takeda Pharmaceutical Co., Ltd. revenue for the last quarter amounts to 6.98 B USD despite the estimated figure of 6.65 B USD. In the next quarter revenue is expected to reach 7.12 B USD.
Yes, you can track Takeda Pharmaceutical Co., Ltd. financials in yearly and quarterly reports right on TradingView.
Like other stocks, TKPHF shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Takeda Pharmaceutical Co., Ltd. stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 18, 2024, the company has 49.10 K employees. See our rating of the largest employees — is Takeda Pharmaceutical Co., Ltd. on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Takeda Pharmaceutical Co., Ltd. technincal analysis shows the strong sell today, and its 1 week rating is strong sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Takeda Pharmaceutical Co., Ltd. stock shows the strong sell signal. See more of Takeda Pharmaceutical Co., Ltd. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on Takeda Pharmaceutical Co., Ltd. future price: according to them, TKPHF price has a max estimate of 39.22 USD and a min estimate of 27.21 USD. Read a more detailed Takeda Pharmaceutical Co., Ltd. forecast: see what analysts think of Takeda Pharmaceutical Co., Ltd. and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Takeda Pharmaceutical Co., Ltd. EBITDA is 8.64 B USD, and current EBITDA margin is 32.84%. See more stats in Takeda Pharmaceutical Co., Ltd. financial statements.